leucine rich repeat containing 37 member A14, pseudogeneGenealiases: []
Q-omics provides the consensus-scored LRRC37A14P profile across patient tissues and cancer cell-line models. LRRC37A14P expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LRRC37A14P is differentially expressed in 5, with the highest sampling consensus in LUAD. Additionally, LRRC37A14P RNA expression shows 6,827 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, LUAD, and STAD as cancer lineages where LRRC37A14P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC37A14P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC37A14P survival associations across molecular data types. LRRC37A14P RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC37A14P RNA expression–survival associations across cancer types. High LRRC37A14P expression shows unfavorable associations in ACC and THCA, but favorable associations in HNSC, STAD, BRCA and LUAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for LRRC37A14P RNA expression.
This table summarizes LRRC37A14P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for LRRC37A14P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC37A14P shows lower tumor expression in LUAD, LUSC and THCA and higher tumor expression in BRCA and STAD. The LUAD box plot shows higher LRRC37A14P RNA expression in normal versus tumor tissue (log2 FC = −0.726, t-test p < 0.001).
This table shows molecular features associated with LRRC37A14P in patient tissues and cancer cell lines. In patient samples, LRRC37A14P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
